Literature DB >> 15023810

Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.

Irene L Katzan1, Maxim D Hammer, Eric D Hixson, Anthony J Furlan, Alex Abou-Chebl, Deborah M Nadzam.   

Abstract

BACKGROUND: Intravenous tissue plasminogen activator (tPA) is the only approved therapy for acute ischemic stroke, although only 2% of patients with stroke receive intravenous tPA nationally.
OBJECTIVE: To determine the rate of tPA use for stroke in the Cleveland, Ohio, community and the reasons why patients were excluded from thrombolysis treatment.
DESIGN: Retrospective cohort study.
SETTING: Community. Subjects Patients admitted because of stroke to the 9 Cleveland Clinic Health System hospitals from June 15, 1999, to June 15, 2000. MAIN OUTCOME MEASURES: Utilization of intravenous tPA and reasons for ineligibility.
RESULTS: There were 1923 admissions for ischemic stroke in the 1-year period. Of these, 288 (15.0%) arrived within the 3-hour time window, and approximately 6.9% were considered eligible for tPA. The most common reasons for exclusion among patients arriving within 3 hours were mild neurologic impairment and rapidly improving symptoms. The overall rate of tPA use among patients presenting within 3 hours was 19.4%, and the rate of use among eligible patients was 43.4% (n = 56). The use of tPA did not differ significantly according to race or sex.
CONCLUSIONS: Only 15% of patients arrived within the 3-hour time window for intravenous tPA, making delay in presentation the most common reason patients were ineligible for i.v. thrombolysis. Neurologic criteria were the second most common group of exclusions. Overall tPA use was low, but it was used in nearly half of all patients with no documented contraindications. Intravenous tPA use in a community setting can compare favorably with the rate of use seen in academic medical settings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023810     DOI: 10.1001/archneur.61.3.346

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  65 in total

1.  Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.

Authors:  Opeolu Adeoye; Richard Hornung; Pooja Khatri; Dawn Kleindorfer
Journal:  Stroke       Date:  2011-06-02       Impact factor: 7.914

2.  Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective.

Authors:  D Jackson; S R Earnshaw; R Farkouh; L Schwamm
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-10       Impact factor: 3.825

3.  Rapid stent-supported revascularization in acute ischemic stroke.

Authors:  B-F M Fitzsimmons; T Becske; P K Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

4.  Patient delay in acute stroke response.

Authors:  T Hemmen
Journal:  Eur J Neurol       Date:  2008-04       Impact factor: 6.089

5.  Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke.

Authors:  Zhenjun Tan; Ryan C Turner; Rachel L Leon; Xinlan Li; Jarin Hongpaisan; Wen Zheng; Aric F Logsdon; Zachary J Naser; Daniel L Alkon; Charles L Rosen; Jason D Huber
Journal:  Stroke       Date:  2013-10-30       Impact factor: 7.914

6.  Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.

Authors:  Phillip A Scott; Shirley M Frederiksen; John D Kalbfleisch; Zhenzhen Xu; William J Meurer; Angela F Caveney; Annette Sandretto; Ann B Holden; Mary N Haan; Ellen G Hoeffner; Sameer A Ansari; David P Lambert; Michael Jaggi; William G Barsan; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-10       Impact factor: 3.451

7.  Thrombolytic effects of a combined therapy with targeted microbubbles and ultrasound in a 6 h cerebral thrombosis rabbit model.

Authors:  Shu-Ting Ren; Li-Hui Long; Mei Wang; Yi-Ping Li; Hao Qin; Hui Zhang; Bo-Bin Jing; Ying-Xue Li; Wei-Jin Zang; Bing Wang; Xin-Liang Shen
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

Review 8.  Performance measures in neuroradiology.

Authors:  D Seidenwurm; P Turski; J Barr; J Connors; M Lev; S Mukherji; E Russell
Journal:  AJNR Am J Neuroradiol       Date:  2007-09       Impact factor: 3.825

9.  Understanding the reasons behind the low utilisation of thrombolysis in stroke.

Authors:  Ashraf Eissa; Ines Krass; Christopher Levi; Jonathan Sturm; Rabsima Ibrahim; Beata Bajorek
Journal:  Australas Med J       Date:  2013-03-31

10.  Ethnic disparities trump other risk factors in determining delay to emergency department arrival in acute ischemic stroke.

Authors:  James E Siegler; Amelia K Boehme; Karen C Albright; Sheryl Martin-Schild
Journal:  Ethn Dis       Date:  2013       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.